Chemomab Therapeutics (CMMB) Total Non-Current Liabilities (2018 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Total Non-Current Liabilities came in at $179000.0 in Q1 2025, down 36.07% YoY from $280000.0 in Q1 2024, and down 14.35% on a QoQ basis from $209000.0 in Q4 2024.
Chemomab Therapeutics (CMMB) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 8 years of Total Non-Current Liabilities data on file, last reported at $179000.0 in Q1 2025.
- Quarterly Total Non-Current Liabilities fell 36.07% year-over-year to $179000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $179000.0 (down 36.07% YoY) and the FY2024 annual result came in at $209000.0, down 33.86% from the prior year.
- Total Non-Current Liabilities slipped to $179000.0 in Q1 2025, from $209000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $328000.0 in Q1 2021 to a low of $5000.0 in Q3 2023.
- A 5-year average of $194588.2 and a median of $209000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slumped 95.76% — and 2024, when it jumped 4500.0%.
- Tracing CMMB's Total Non-Current Liabilities over 5 years: stood at $237000.0 in 2021, then plunged by 61.6% to $91000.0 in 2022, then surged by 247.25% to $316000.0 in 2023, then tumbled by 33.86% to $209000.0 in 2024, then decreased by 14.35% to $179000.0 in 2025.
- The last three Total Non-Current Liabilities figures came in at $179000.0 (Q1 2025), $209000.0 (Q4 2024), and $230000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 179,000.00 |
| Dec 31, 2024 | 209,000.00 |
| Sep 30, 2024 | 230,000.00 |
| Jun 30, 2024 | 251,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Dec 31, 2023 | 316,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | 62,000.00 |
| Dec 31, 2022 | 91,000.00 |
| Sep 30, 2022 | 118,000.00 |
| Jun 30, 2022 | 148,000.00 |
| Mar 31, 2022 | 203,000.00 |
| Dec 31, 2021 | 237,000.00 |
| Sep 30, 2021 | 298,000.00 |
| Jun 30, 2021 | 320,000.00 |
| Mar 31, 2021 | 328,000.00 |
| Dec 31, 2020 | 358,000.00 |
| Dec 31, 2019 | 725,000.00 |
| Sep 30, 2019 | 6.26 Mn |